P2Y12 vs. Aspirin: Heart Attack & Stroke Prevention
- For patients with coronary artery disease, taking a P2Y12 inhibitor anti-clotting drug is linked to lower rates of cardiovascular death, heart attack, and stroke compared to aspirin, according...
- P2Y12 inhibitors are frequently enough administered with aspirin ("dual therapy") following percutaneous coronary intervention (PCI), a procedure to open blocked coronary arteries, to prevent cardiovascular events.
- Researchers analyzed data from five randomized clinical trials involving 16,117 patients (average age 65; 24% women) who were prescribed either a P2Y12 inhibitor (clopidogrel or ticagrelor) or aspirin...
Breakthrough research reveals that for coronary artery disease patients, P2Y12 inhibitors offer superior protection against cardiovascular death, heart attack, and stroke, outperforming aspirin. This compelling study, published in The BMJ, indicates a significant reduction in adverse events without increasing the risk of major bleeding. Scientists analyzed five clinical trials, involving over 16,000 patients, to compare P2Y12 inhibitors like clopidogrel and ticagrelor against aspirin following initial dual therapy after PCI. News Directory 3 brings you this critical update, highlighting a 23% reduction in combined risk for heart attack, stroke, or cardiovascular death with P2Y12 inhibitors alone. Discover what’s next in the future of secondary prevention post-PCI.
P2Y12 Inhibitors Offer Superior Protection Against Heart Attack and Stroke
Updated June 05, 2025
Credit: Pixabay/CC0 Public Domain
For patients with coronary artery disease, taking a P2Y12 inhibitor anti-clotting drug is linked to lower rates of cardiovascular death, heart attack, and stroke compared to aspirin, according to a study in The BMJ. The research found no increased risk of major bleeding with P2Y12 inhibitors.
P2Y12 inhibitors are frequently enough administered with aspirin (“dual therapy”) following percutaneous coronary intervention (PCI), a procedure to open blocked coronary arteries, to prevent cardiovascular events. While patients typically switch to lifelong aspirin after several months,some evidence suggests a P2Y12 inhibitor might be more effective for long-term prevention of cardiovascular disease.
Researchers analyzed data from five randomized clinical trials involving 16,117 patients (average age 65; 24% women) who were prescribed either a P2Y12 inhibitor (clopidogrel or ticagrelor) or aspirin after dual therapy following PCI. The study focused on the effectiveness of P2Y12 inhibitors.
After roughly four years of follow-up, P2Y12 inhibitor therapy showed a 23% reduction in the combined risk of cardiovascular death, heart attack, or stroke, compared to aspirin. Major bleeding risks were similar between the two treatments. The study highlights the benefits of anti-clotting drugs.
The findings suggest that for every 46 patients using a P2Y12 inhibitor instead of aspirin after dual therapy,one cardiovascular death,heart attack,or stroke could be averted.
Analyzing individual outcomes revealed that P2Y12 inhibitor therapy reduced heart attacks and strokes compared to aspirin. however, all-cause death, cardiovascular death, and stent thrombosis rates were comparable between the two treatments.
The researchers noted that some adjustments to the original trial designs were necessary to standardize data, and certain characteristics of trial populations might limit the generalizability of the results. Though, they observed no notable difference in major bleeding between the groups.Consistent results across various analyses, considering factors like age, sex, region, smoking, prior heart attack or stroke, underlying conditions, and medication history, suggest the findings are reliable.
“this study supports preferential P2Y12 inhibitor monotherapy prescription over aspirin due to reductions in major adverse cardiac and cerebrovascular events (MACCE) without increasing major bleeding in the medium term,” researchers stated in a linked editorial.
The editorial also cautioned that “medium-term efficacy does not necessarily extend lifelong, which is the duration we advise patients to continue these medications.”
What’s next
The researchers suggest a large-scale, globally representative trial directly comparing different monotherapy strategies, including discontinuation, with extended follow-up to better understand the long-term impact of P2Y12 inhibitor monotherapy across the treatment class for secondary prevention following PCI.